INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN1h ago
Corporate insider
LP

Lyssikatos Joseph P

CHIEF SCIENTIFIC OFFICERCIK 0001967150

EDGAR filingsOpen in network
Disclosed transactions12
Buys / sells0 / 10
Max Insider Score21
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
8
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Grant or award
A—
112.5K sh
Feb 12, 2026Feb 17, 2026
traded Feb 12, 2026
+5dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Enliven Therapeutics, Inc.CHIEF SCIENTIFIC OFFICER · Nov 21, 2025
8
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Grant or award
A
—
18.8K sh
Feb 12, 2026
Feb 17, 2026
traded Feb 12, 2026
+5d
SEC FORM 4

Evidence

1
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$145K
5,000 sh
Feb 6, 2026Feb 10, 2026
traded Feb 6, 2026
+4dSEC FORM 4

Evidence

6
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$145K
5,491 sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

9
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$390K
14.5K sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

9
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$151K
7,500 sh
Jan 8, 2026Jan 12, 2026
traded Jan 8, 2026
+4dSEC FORM 4

Evidence

19
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.46M
50.0K sh
Jan 9, 2026Jan 12, 2026
traded Jan 9, 2026
+3dSEC FORM 4

Evidence

15
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.03M
41.2K sh
Jan 9, 2026Jan 12, 2026
traded Jan 9, 2026
+3dSEC FORM 4

Evidence

12
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$842K
33.8K sh
Jan 8, 2026Jan 12, 2026
traded Jan 8, 2026
+4dSEC FORM 4

Evidence

9
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$84K
5,000 sh
Dec 19, 2025Dec 23, 2025
traded Dec 19, 2025
+4dSEC FORM 4

Evidence

15
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$11K
492 sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

21
LP
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$268K
12.0K sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence